ONCAlert | 2017 San Antonio Breast Cancer Symposium

Alternative Sunitinib Scheduling for mRCC

Eric Jonasch, MD
Published Online:9:55 AM, Tue March 28, 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.